Last checked at 31 Mar 2023 14:45
Bioventix plc
("Bioventix" or the "Company")
Director/PDMR Shareholding
Bioventix plc (BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, was notified on 31 March 2023 of the following transactions in its ordinary shares of 5 pence each ("Ordinary Shares"):
Director | Role | Ordinary Shares sold | Average sale price per Ordinary Share | Ordinary Shares subsequently held | Percentage of issued share capital subsequently held |
Ian Nicholson and Persons Closely Associated | Non-Executive Chairman | 2,500 | 3,900 | 13,000 | 0.2% |
The notifications below, which have been made in accordance with the requirements of the Market Abuse Regulation, provide further details.
For further information please contact:
Bioventix plc Peter Harrison Bruce Hiscock |
Chief Executive Officer Chief Financial Officer | Tel: 01252 728 001 |
finnCap Ltd Geoff Nash/Simon Hicks Alice Lane |
Corporate Finance ECM | Tel: 020 7220 0500 |
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
1 | Details of the person discharging managerial responsibilities ("PDMR") / person closely associated ("PCA") | |||||
a) | Name | Ian Nicholson | ||||
2. | Reason for the Notification | |||||
a) | Position/status | Chairman | ||||
b) | Initial notification/Amendment | Initial notification | ||||
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | Bioventix plc | ||||
b) | LEI | 213800225MHX7LZQY108 | ||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the Financial instrument, type of instrument | Ordinary Shares of 5 pence each | ||||
Identification code | GB00B4QVDF07 | |||||
b) | Nature of the transaction | Sale of Ordinary Shares | ||||
c) | Price(s) and volume(s) |
| ||||
d) | Aggregated information: · Aggregated volume · Price | See 4(c) | ||||
e) | Date of the transaction | 31 March 2023 | ||||
f) | Place of the transaction | London Stock Exchange, AIM Market (XLON) | ||||
1 | Details of the person discharging managerial responsibilities ("PDMR") / person closely associated ("PCA") | |||||
a) | Name | Catherine Nicholson | ||||
2. | Reason for the Notification | |||||
a) | Position/status | PCA of Ian Nicholson, Chairman | ||||
b) | Initial notification/Amendment | Initial notification | ||||
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | Bioventix plc | ||||
b) | LEI | 213800225MHX7LZQY108 | ||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the Financial instrument, type of instrument | Ordinary Shares of 5 pence each | ||||
Identification code | GB00B4QVDF07 | |||||
b) | Nature of the transaction | Sale of Ordinary Shares | ||||
c) | Price(s) and volume(s) |
| ||||
d) | Aggregated information: · Aggregated volume · Price | See 4(c) | ||||
e) | Date of the transaction | 31 March 2023 | ||||
f) | Place of the transaction | London Stock Exchange, AIM Market (XLON) | ||||